This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kijima, T. Articles by Kishimoto, T. Search for Related Content PubMed PubMed Citation Articles by Kijima, T. Articles by Kishimoto, T.

Application of the Cre Recombinase/loxP System Further Enhances Antitumor Effects in Cell Type-specific Gene Therapy against Carcinoembryonic Antigen-producing Cancer¹

Department of Molecular Medicine, Osaka University Medical School, Osaka 565-0871 [T. Kij., T. O., K. N., T. Ku., T. F., H. G., I. T.]; Department of Internal Medicine, Osaka Prefectural General Hospital, Osaka 558-0056 [Y. T.]; and Osaka University, Osaka 565-0871 [T. Kis.], Japan

A considerable number of studies of cancer have shown that the cell type-specific promoter is an effective tool for selective expression of foreign genes in tumor cells. However, few reports have demonstrated significant in vivo antitumor effects using this strategy thus far, possibly because the low activity of such a promoter results in insufficient expression of genes in cancer cells as well as in insignificant antitumor effects, even when the cells are infected by highly efficient gene transfer methods. To overcome this problem, we used the Cre/loxP system for the cell type-specific gene therapy against carcinoembryonic antigen (CEA)-producing cancer. We constructed a pair of recombinant Ads. One expresses the Cre recombinase (Cre) gene under the control of the CEA promoter (Ad.CEA-Cre). The other contains the herpes simplex virus thymidine kinase (HSV-TK) gene separated from the strong CAG promoter by insertion of the neomycin resistance (neo) gene (Ad.lox-TK). The HSV-TK gene of the latter Ad is designed to be activated through excisional deletion of the neo gene by Cre enzyme released from the former one only when CEA-producing cells are infected simultaneously with these Ads. Coinfection by these Ads rendered a human CEA-producing cancer cell line 8.4-fold more sensitive to ganciclovir (GCV) compared with infection by Ad.CEA-TK alone, the HSV-TK gene of which is directly regulated by the CEA promoter. On the other hand, coinfection with these Ads did not significantly change the GCV sensitivity of non-CEA-producing cells. Intratumoral injection of Ad.CEA-Cre combined with Ad.lox-TK followed by GCV treatment almost completely eradicated CEA-producing tumors established in the subcutis of athymic mice, whereas intratumoral injection of Ad.CEA-TK with GCV administration at most retarded the growth of inoculated tumors. These results suggest distinct advantages of the Cre/loxP system applied in the conventional cell type-specific gene therapy against cancer.

This article has been cited by other articles:

				J. M. Lambert, R. S. Bongers, and M. Kleerebezem Cre-lox-Based System for Multiple Gene Deletions and Selectable-Marker Removal in Lactobacillus plantarum Appl. Envir. Microbiol., February 15, 2007; 73(4): 1126 - 1135. [Abstract] [Full Text] [PDF]

				M. Bordonaro, D. L. Lazarova, and A. C. Sartorelli Pharmacological and genetic modulation of Wnt-targeted Cre-Lox-mediated gene expression in colorectal cancer cells Nucleic Acids Res., May 11, 2004; 32(8): 2660 - 2674. [Abstract] [Full Text] [PDF]

				X. Lin, A. H. Fischer, K.-y. Ryu, J.-y. Cho, T. J. Sferra, R. T. Kloos, E. L. Mazzaferri, and S. M. Jhiang Application of the Cre/loxP System to Enhance Thyroid-Targeted Expression of Sodium/Iodide Symporter J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2344 - 2350. [Abstract] [Full Text] [PDF]

				D. Xu, D. Falke, and R. L. Juliano P53-Dependent Cell-Killing by Selective Repression of Thymidine Kinase and Reduced Prodrug Activation Mol. Pharmacol., August 1, 2003; 64(2): 289 - 297. [Abstract] [Full Text] [PDF]

				M. K. Nyati, A. Sreekumar, S. Li, M. Zhang, S. D. Rynkiewicz, A. M. Chinnaiyan, A. Rehemtulla, and T. S. Lawrence High and Selective Expression of Yeast Cytosine Deaminase under a Carcinoembryonic Antigen Promoter-Enhancer Cancer Res., April 1, 2002; 62(8): 2337 - 2342. [Abstract] [Full Text] [PDF]

				W. Yang, S. Arii, A. Mori, K. Furumoto, T. Nakao, N. Isobe, T. Murata, H. Onodera, and M. Imamura sFlt-1 Gene-transfected Fibroblasts: A Wound-specific Gene Therapy Inhibits Local Cancer Recurrence Cancer Res., November 1, 2001; 61(21): 7840 - 7845. [Abstract] [Full Text] [PDF]

				K. Ueda, M. Iwahashi, M. Nakamori, M. Nakamura, I. Matsuura, H. Yamaue, and H. Tanimura Carcinoembryonic Antigen-specific Suicide Gene Therapy of Cytosine Deaminase/5-Fluorocytosine Enhanced by the Cre/loxP System in the Orthotopic Gastric Carcinoma Model Cancer Res., August 1, 2001; 61(16): 6158 - 6162. [Abstract] [Full Text] [PDF]

				M. Nakano, K. Odaka, M. Ishimura, S. Kondo, N. Tachikawa, J. Chiba, Y. Kanegae, and I. Saito Efficient gene activation in cultured mammalian cells mediated by FLP recombinase-expressing recombinant adenovirus Nucleic Acids Res., April 1, 2001; 29(7): e40 - e40. [Abstract] [Full Text] [PDF]

				W. C. Russell Update on adenovirus and its vectors J. Gen. Virol., November 1, 2000; 81(11): 2573 - 2604. [Full Text]